Angiotensin-Converting Enzyme Inhibitors

"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Descriptor ID	D000806
MeSH Number(s)	D27.505.519.389.745.085
Concept/Terms	Angiotensin-Converting Enzyme Inhibitors Angiotensin-Converting Enzyme Inhibitors Angiotensin Converting Enzyme Inhibitors Inhibitors, Kininase II Kininase II Antagonists Kininase II Inhibitors Angiotensin I-Converting Enzyme Inhibitors Angiotensin I Converting Enzyme Inhibitors Antagonists, Angiotensin-Converting Enzyme Antagonists, Angiotensin Converting Enzyme Antagonists, Kininase II Inhibitors, ACE ACE Inhibitors Inhibitors, Angiotensin-Converting Enzyme Enzyme Inhibitors, Angiotensin-Converting Inhibitors, Angiotensin Converting Enzyme Angiotensin-Converting Enzyme Antagonists Angiotensin Converting Enzyme Antagonists Enzyme Antagonists, Angiotensin-Converting

Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]
Angiotensin-Converting Enzyme Inhibitors [D27.505.519.389.745.085]

Below are MeSH descriptors whose meaning is related to "Angiotensin-Converting Enzyme Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".

Angiotensin-Converting Enzyme Inhibitors
Vasopeptidase Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.

Bar chart showing 67 publications over 26 distinct years, with a maximum of 7 publications in 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1999	0	1	1
2001	1	0	1
2002	2	1	3
2003	4	1	5
2004	2	2	4
2005	0	1	1
2006	2	5	7
2007	1	4	5
2008	3	0	3
2009	0	1	1
2010	0	3	3
2011	2	0	2
2013	0	1	1
2014	1	1	2
2015	1	5	6
2016	1	1	2
2017	0	1	1
2018	3	1	4
2019	2	3	5
2020	0	1	1
2021	0	1	1
2022	0	3	3
2023	1	1	2
2024	0	1	1
2025	0	1	1

Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.

Mayhand KN, Alicic RZ, Kornowske LM, Jones CR, Daratha KB, Reynolds CL, Nicholas SB, Thorpe RJ, Bui AAT, Norris KC, Tuttle KR. Clinical characteristics and CKD care delivery in African American and American Indian or Alaska Native patients: A real-world cohort study. BMC Nephrol. 2025 Jul 21; 26(1):407.

View in: PubMed
Zhao MH, Chen W, Cheng H, Liu BC, Mao ZG, Tian Z, Xu G, Zhou JM. A Chinese Multi-Specialty Delphi Consensus to Optimize RAASi Usage and Hyperkalaemia Management in Patients with Chronic Kidney Disease and Heart Failure. Chin Med Sci J. 2024 Jun 30; 39(2):79-90.

View in: PubMed
January SE, Hubbard J, Fester KA, Dubrawka CA, Vazquez Guillamet R, Kulkarni HS, Hachem RR. Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction. J Pharm Pract. 2024 Oct; 37(5):1170-1174.

View in: PubMed
Nicholas SB, Daratha KB, Alicic RZ, Jones CR, Kornowske LM, Neumiller JJ, Fatoba ST, Kong SX, Singh R, Norris KC, Tuttle KR. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020. Diabetes Obes Metab. 2023 10; 25(10):2970-2979.

View in: PubMed
Chen D, Yun X, Lee D, DiCostanzo JR, Donini O, Shikuma CM, Thompson K, Lehrer AT, Shimoda L, Suk JS. Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections. Mol Pharm. 2023 01 02; 20(1):750-757.

View in: PubMed
Sood A, Qualls C, Murata A, Kroth PJ, Mao J, Schade DS, Murata G. Potential for repurposing oral hypertension/diabetes drugs to decrease asthma risk in obesity. J Asthma. 2023 04; 60(4):802-810.

View in: PubMed
Matanes F, Khan MB, Siddiqui M, Dudenbostel T, Calhoun D, Oparil S. An Update on Refractory Hypertension. Curr Hypertens Rep. 2022 07; 24(7):225-234.

View in: PubMed
Graham DJ, Izurieta HS, Muthuri SG, Zhang D, Sandhu AT, Lu Y, Zhao Y, Feng Y, Eworuke E, Lyu H, Gandotra C, Smith ER, Avagyan A, Wernecke M, Kelman JA, Forshee RA, MaCurdy TE. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension. J Gen Intern Med. 2021 12; 36(12):3802-3809.

View in: PubMed
He B, Garmire L. Prediction of repurposed drugs for treating lung injury in COVID-19. F1000Res. 2020; 9:609.

View in: PubMed
Yap J, Keh YS, Shen T, Lam CSP, Chia SY, Jaufeerally FR, Ong W, Sim D, Ching CK. QRS duration and cardiovascular mortality in Asian patients with heart failure and preserved and reduced ejection fraction. Cardiol J. 2021; 28(1):166-169.

View in: PubMed

People

Explore

Similar Concepts

Top Journals